Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
CONSTELLATION PHARMACEUTICALS INC (CNST) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/15/2021 8-K Resignation/termination of a director
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Amended and Restated Certificate of Incorporation of Constellation Pharmaceuticals, Inc",
"Amended and Restated Bylaws of Constellation Pharmaceuticals, Inc"
06/02/2021 8-K Quarterly results
06/02/2021 8-K Quarterly results
12/07/2020 8-K Other Events  Interactive Data
11/18/2020 8-K Entry into a Material Definitive Agreement  Interactive Data
11/09/2020 8-K Termination of a Material Definitive Agreement  Interactive Data
06/17/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : June 16, 2020 Constellation Pharmaceuticals, Inc. Delaware 001-38584 26-1741721 215 First Street, Suite 200 Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 714-0555 Not applicable",
"Underwriting Agreement, June 16, 2020, by and among the Company and J.P. Morgan Securities LLC, Jefferies LLC, Cowen and Company, LLC and RBC Capital Markets, LLC",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Massachusetts, June 16, 2020 - Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has priced an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $35.00 per share, for total gross proceeds of $192.5 million, before deducting underwriting discounts and commissions and expenses payable by Constellation. All of the shares in the offering are being sold by Constellation. In addition, Constellation has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of its common stock at the public offer..."
06/15/2020 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : June 12, 2020 Constellation Pharmaceuticals, Inc. Delaware 001-38584 26-1741721 215 First Street, Suite 200 Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 714-0555 Not applicable"
06/08/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : June 4, 2020 Constellation Pharmaceuticals, Inc. Delaware 001-38584 26-1741721 215 First Street, Suite 200 Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 714-0555 Not applicable"
06/04/2020 8-K Submission of Matters to a Vote of Security Holders
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : June 4, 2020 Constellation Pharmaceuticals, Inc. Delaware 001-38584 26-1741721 215 First Street, Suite 200 Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 714-0555 Not applicable"
05/14/2020 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : May 14, 2020 Constellation Pharmaceuticals, Inc. Delaware 001-38584 26-1741721 215 First Street, Suite 200 Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 714-0555 Not applicable"
05/06/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : May 6, 2020 Constellation Pharmaceuticals, Inc. Delaware 001-38584 26-1741721 215 First Street, Suite 200 Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 714-0555 Not applicable",
"Constellation Pharmaceuticals Announces First-Quarter 2020 Financial Results"
04/06/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Constellation Pharmaceuticals Announces Appointment of Dr. Richard Levy to Board of Directors CAMBRIDGE, Massachusetts, April 6, 2020 - Constellation Pharmaceuticals , Inc. , a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Richard Levy, M.D., has been appointed to its Board of Directors. Dr. Levy has nearly 30 years of experience in the pharmaceutical and biotechnology sectors, where he held senior clinical development positions at Incyte, Celgene, DuPont Pharmaceuticals, and Sandoz / Novartis. He served as Executive Vice President and Chief Drug Development and Medical Officer at Incyte, where from 2003 to 2016 he was responsible for the expansion of the clinical development portfolio in oncolog..."
01/13/2020 8-K Investor presentation
Docs: "Presentation (furnished herewith)"
01/03/2020 8-K Quarterly results
12/11/2019 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : December 10, 2019 Constellation Pharmaceuticals, Inc. Delaware 001-38584 26-1741721 215 First Street, Suite 200 Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 714-0555 Not applicable",
"Underwriting Agreement, by and among the Company and J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Massachusetts, December 10, 2019 - Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has priced an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $34.50 per share, for total gross proceeds of $224.3 million, before deducting underwriting discounts and commissions and expenses payable by Constellation. All of the shares in the offering are being sold by Constellation. In addition, Constellation has granted the underwriters a 30-day option to purchase up to 975,000 additional shares of its common stock at the public o..."
12/09/2019 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : December 9, 2019 Constellation Pharmaceuticals, Inc. Delaware 001-38584 26-1741721 215 First Street, Suite 200 Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 714-0555 Not applicable"
10/01/2019 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Securities Purchase Agreement, by and among the Company and the other parties thereto",
"Registration Rights Agreement, by and among the Company and the other parties thereto",
"Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing Investors CAMBRIDGE, Massachusetts, October 1, 2019 - Constellation Pharmaceuticals , Inc. , a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has entered into a securities purchase agreement with a group of institutional investors for the private placement of $65 million of shares of its common stock. The transaction is expected to close on or about October 3, 2019, subject to the satisfaction of customary closing conditions. The private placement is being led by Venrock Healthcare Capital Partners and includes Bain Capital Life Sciences and affiliates of The Column Group. In this private placement, the ..."
09/24/2019 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : September 24, 2019 Constellation Pharmaceuticals, Inc. Delaware 001-38584 26-1741721 215 First Street, Suite 200 Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 714-0555 Not applicable",
"900 800 700 600 500"
09/20/2019 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Docs: "Q"
08/07/2019 8-K Investor presentation
Docs: "Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2019 Financial Results",
"Corporate Overview (furnished herewith)"
06/19/2019 8-K Entry into a Material Definitive Agreement
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : June 17, 2019 Constellation Pharmaceuticals, Inc. Delaware 001-38584 26-1741721 215 First Street, Suite 200 Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 714-0555 Not applicable"
06/10/2019 8-K Submission of Matters to a Vote of Security Holders
05/16/2019 8-K Investor presentation
Docs: "Constellation Pharmaceuticals Provides Interim Update of Data for CPI-0610 in ASCO and EHA Abstracts",
"Corporate Overview (furnished herewith)",
"Abstract published by EHA titled CPI-0610, a BromoDomain and Extraterminal Domain (BET) Inhibitor, Reduces Pro-Inflammatory Cytokines, Bone Marrow Fibrosis and the Number of Transfusions in Myelofibrosis Patients (furnished herewith)"
05/15/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Abstract #260583, ASCO Annual Meeting, May 31-June 4, 2019 | Chicago, Illinois. A Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Protein Inhibitor (BETi) alone or with Ruxolitinib (RUX), in Patients with Myelofibrosis (MF) (furnished herewith)"
05/08/2019 8-K Investor presentation
Docs: "Constellation Pharmaceuticals Announces First-Quarter 2019 Financial Results",
"Corporate Overview dated May 2019 (furnished herewith)"
04/01/2019 8-K Investor presentation
Docs: "Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial of CPI-1205 at AACR Meeting",
"Corporate Overview dated April 2019 (furnished herewith)"
03/21/2019 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Loan and Security Agreement, by and among the Registrant, the several banks and other financial institutions or entities from time to time parties thereto and Hercules Capital, Inc"
03/14/2019 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : March 14, 2019 Constellation Pharmaceuticals, Inc. Delaware 001-38584 26-1741721 215 First Street, Suite 200 Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 714-0555 Not applicable",
"Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial Results CAMBRIDGE, Massachusetts, March 14, 2019 - Constellation Pharmaceuticals , Inc. , a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its fourth-quarter and full-year 2018 financial results. “2019 is a year of data for Constellation, and our clinical programs are making significant progress and approaching important readouts,” said Jigar Raythatha, president and chief executive officer of Constellation Pharmaceuticals. “We are excited by preliminary data from our first four patients from the MANIFEST clinical trial, each showing one or more of the following: conversion from transfusion dependence to transfusion ind...",
"Corporate Overview dated March 2019"
02/20/2019 8-K Quarterly results
01/07/2019 8-K Investor presentation
Docs: "Corporate Overview dated January 2019 (furnished herewith)",
"Corporate Overview dated January 2019 (furnished herewith)"
01/03/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs"
12/10/2018 8-K Investor presentation
Docs: "FORM 8-K",
"Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer • Dosing has begun in a randomized study of CPI-1205 / enzalutamide combination versus enzalutamide alone in second-line mCRPC • Single-arm CPI-1205 / abiraterone / prednisone combination added to potentially address low response rates and short duration of response in second-line mCRPC with abiraterone alone • Preliminary Phase 1b results suggest CPI-1205 is well-tolerated, with a robust PK/PD profile and clinical activity in both arms in second-line mCRPC CAMBRIDGE, Massachusetts, December 10, 2018 - Constellation Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel...",
"Corporate Overview dated December 2018 (furnished herewith)"
11/01/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : November 1, 2018 Constellation Pharmaceuticals, Inc. Delaware 001-38584 26-1741721 215 First Street, Suite 200 Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 714-0555 Not applicable",
"Constellation Pharmaceuticals Receives FDA Fast Track Designation for CPI-0610 in Treatment of Myelofibrosis"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy